Preferred Label : sacituzumab govitecan;
UNII : M9BYU8XDQ6;
Origin ID : C000608132;
UMLS CUI : C4086837;
ATC code(s)
- Currated CISMeF NLP mapping
- MeSH term(s) associated for indexing
- Record concept(s)
- Semantic type(s)
- UMLS correspondences (same concept)
https://www.has-sante.fr/jcms/p_3490834/fr/trodelvy-sacituzumab-govitecan-cancer-du-sein
2024
false
false
false
France
adult
treatment outcome
insurance, health, reimbursement
infusions, intravenous
sacituzumab govitecan
HER2/Neu Negative
Hormone Receptor Positive
evaluation of the transparency committee
breast neoplasms
sacituzumab govitecan
---
https://www.has-sante.fr/jcms/p_3455287/fr/trodelvy-sacituzumab-govitecan-cancer-du-sein
2023
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
sacituzumab govitecan
sacituzumab govitecan
triple negative breast neoplasms
insurance, health, reimbursement
Unresectable Triple-Negative Breast Carcinoma
Metastatic Triple-Negative Breast Carcinoma
neoplasm metastasis
antineoplastic agents
---
https://ansm.sante.fr/tableau-acces-derogatoire/sacituzumab-govitecan-180-mg-poudre-pour-solution-a-diluer-pour-perfusion-trodelvy
2023
false
false
false
France
French
summary of product characteristics
package leaflet
insurance, health, reimbursement
sacituzumab govitecan
adult
breast neoplasms
guidelines for drug use
sacituzumab govitecan
antineoplastic agents
Unresectable HER2-Negative Breast Carcinoma
Metastatic HER2-Negative Breast Carcinoma
Unresectable Hormone Receptor-Positive Breast Carcinoma
Metastatic Hormone Receptor-Positive Breast Carcinoma
infusions, intravenous
triple negative breast neoplasms
Product containing only sacituzumab govitecan in parenteral dose form (medicinal product
form)
Unresectable Triple-Negative Breast Carcinoma
Metastatic Triple-Negative Breast Carcinoma
Refractory Triple-Negative Breast Carcinoma
---
https://www.has-sante.fr/jcms/p_3418105/fr/trodelvy-sacituzumab-govitecan-cancer-du-sein
2023
false
false
false
France
insurance, health, reimbursement
treatment outcome
sacituzumab govitecan
antineoplastic agents
Unresectable Hormone Receptor-Positive Breast Carcinoma
HER2-Negative Breast Carcinoma
adult
neoplasm metastasis
Metastatic Hormone Receptor-Positive Breast Carcinoma
evaluation of the transparency committee
breast neoplasms
sacituzumab govitecan
---
https://www.has-sante.fr/jcms/p_3341351/fr/trodelvy-sacituzumab-govitecan-cancer-du-sein-triple-negatif
2022
false
false
false
France
treatment outcome
insurance, health, reimbursement
triple negative breast neoplasms
adult
Unresectable Triple-Negative Breast Carcinoma
Metastatic Triple-Negative Breast Carcinoma
Refractory Triple-Negative Breast Carcinoma
sacituzumab govitecan
Antineoplastic Agents, Immunological
infusions, intravenous
economic evaluation
evaluation of the transparency committee
sacituzumab govitecan
---
https://www.has-sante.fr/jcms/p_3348651/fr/trodelvy-sacituzumab-govitecan-cancer-du-sein#xtor=EPR-1-[L'actu%20de%20la%20HAS]-20220630
2022
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
insurance, health, reimbursement
sacituzumab govitecan
triple negative breast neoplasms
package leaflet
summary of product characteristics
adult
infusions, intravenous
Antineoplastic Agents, Immunological
sacituzumab govitecan
Refractory Triple-Negative Breast Carcinoma
Metastatic Triple-Negative Breast Carcinoma
Unresectable Triple-Negative Breast Carcinoma
---
https://www.ema.europa.eu/en/medicines/human/EPAR/trodelvy
2022
false
false
false
Netherlands
French
English
sacituzumab govitecan
sacituzumab govitecan
sacituzumab govitecan
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
antineoplastic agents
antineoplastic agents
adult
aged
triple negative breast neoplasms
Metastatic Triple-Negative Breast Carcinoma
Unresectable Triple-Negative Breast Carcinoma
Refractory Triple-Negative Breast Carcinoma
infusions, intravenous
continuity of patient care
drug monitoring
product surveillance, postmarketing
pregnancy
breast feeding
drug interactions
Product containing only sacituzumab govitecan in parenteral dose form (medicinal product
form)
SN 38
topoisomerase I inhibitors
drug evaluation, preclinical
---
https://ansm.sante.fr/actualites/traitement-du-cancer-du-sein-triple-negatif-autorisation-en-acces-precoce-du-medicament-trodelvy-sacituzumab-govitecan
2021
false
false
false
France
French
sacituzumab govitecan
drug information
drug approval
france
triple negative breast neoplasms
sacituzumab govitecan
camptothecin
camptothecin
immunoconjugates
antibodies, monoclonal, humanized
---
https://www.cadth.ca/fr/sacituzumab-govitecan
2021
false
false
false
Canada
French
drug information
triple negative breast neoplasms
sacituzumab govitecan
sacituzumab govitecan
camptothecin
camptothecin
immunoconjugates
antibodies, monoclonal, humanized
---
https://ansm.sante.fr/actualites/traitement-du-cancer-du-sein-triple-negatif-lansm-delivre-de-nouvelles-atu-nominatives-pour-trodelvy-sacituzumab-govitecan
2021
false
false
false
France
French
triple negative breast neoplasms
sacituzumab govitecan
Product containing only sacituzumab govitecan (medicinal product)
drug information
sacituzumab govitecan
camptothecin
camptothecin
immunoconjugates
antibodies, monoclonal, humanized
---
https://www.has-sante.fr/jcms/p_3284598/fr/trodelvy-180-mg-sacituzumab-govitecan
2021
false
false
false
France
sacituzumab govitecan
evaluation of the transparency committee
sacituzumab govitecan
camptothecin
immunoconjugates
antibodies, monoclonal, humanized
treatment outcome
drug approval
france
adult
antineoplastic agents
triple negative breast neoplasms
infusions, intravenous
Product containing only sacituzumab govitecan in parenteral dose form (medicinal product
form)
Metastatic Triple-Negative Breast Carcinoma
Unresectable Triple-Negative Breast Carcinoma
---
